Search for: "Doe v. Mylan Pharmaceuticals, Inc."
Results 41 - 60
of 163
Sort by Relevance
|
Sort by Date
14 Nov 2016, 9:16 am
Kraft Food Brands Group LLC, No 16-341 (Does the general and broad definition of “residence” found in 28 U.S.C. 1391(c) apply to the patent venue statute 1400(b)) Civil Procedure – Personal Jurisdiction: Mylan Pharmaceuticals, et al. v. [read post]
13 Oct 2016, 6:50 am
Lee, No. 16-446 (Eligibility of new use of old manufacture – blackjack game) Personal Jurisdiction: Mylan Pharmaceuticals, et al. v. [read post]
28 Sep 2016, 8:39 am
Amgen Inc., et al., No. 16-332 (effectively extending exclusivity to 12 1/2 years; complement to the Sandoz petition) Mylan Pharmaceuticals, et al. v. [read post]
28 Jun 2016, 6:41 am
Momenta Pharmaceuticals, Inc., et al., No. 15-1402 (scope of 271(e) safe harbor) Exhaustion: Impression Products, Inc. v. [read post]
3 Jun 2016, 6:40 am
Momenta Pharmaceuticals, Inc., et al., No. 15-1402 (scope of 271(e) safe harbor) Exhaustion: Impression Products, Inc. v. [read post]
18 May 2016, 8:19 am
Lexmark International, Inc., No. 15-1189 (unreasonable restraints on downstream uses) Obviousness: Cubist Pharmaceuticals, Inc. v. [read post]
3 May 2016, 9:00 pm
Their practices emphasize pharmaceutical patent counseling, patent procurement, and patent litigation. [2] Acorda Therapeutics Inc. et al. v. [read post]
3 May 2016, 1:42 am
Lexmark International, Inc., No. 15-1189 (unreasonable restraints on downstream uses) Obviousness: Cubist Pharmaceuticals, Inc. v. [read post]
2 May 2016, 6:17 am
The Federal Circuit held that Mylan Pharmaceuticals, Inc. [read post]
18 Apr 2016, 9:58 am
Lexmark International, Inc., No. 15-1189 (unreasonable restraints on downstream uses) Obviousness: Cubist Pharmaceuticals, Inc. v. [read post]
1 Apr 2016, 8:22 am
Lexmark International, Inc., No. 15-1189 (unreasonable restraints on downstream uses) Obviousness: Cubist Pharmaceuticals, Inc. v. [read post]
17 Mar 2016, 2:45 am
Amgen Inc., et al., No. 15-1039 (Does the notice requirement of the BPCIA create an effective six-month exclusivity post-FDA approval?) [read post]
4 Mar 2016, 12:25 pm
Apotex Inc., No. 15-281 Mylan Pharmaceuticals Inc. v. [read post]
19 Feb 2016, 11:57 am
Isonas, Inc., 2014 WL 10988340 (C.D. [read post]
1 Feb 2016, 10:43 am
Cir. 2012) (quotingAmgen Inc. v. [read post]
9 Nov 2015, 7:39 am
Merck Sharp & Dohme v Ono Pharmaceutical [2015] EWHC 2973 (Pat), decided on 22 October by Mr Justice Birss in the Patents Court, England and Wales, is a decidedly unbifurcated ruling, being a full-blooded infringement-and-invalidity action running to 243 paragraphs. [read post]
6 Nov 2015, 6:58 am
Therefore, it was not obvious to test pregabalin – it might be obvious to test gabapentin, but even here the judge considered that the skilled team would have little expectation of success.InsufficiencyAccording to the caselaw relating to sufficiency developed in MedImmune Ltd v Novartis Pharmaceuticals UK Ltd [2011] EWHC 1699 (Pat) at [458]-[484] and summarised in Sandvik Intellectual Property AB v Kennametal UK Ltd [2011] EWHC 3311 (Pat) at… [read post]
5 Nov 2015, 6:00 am
Mylan Pharmaceuticals Inc. v. [read post]
14 May 2015, 4:00 am
In Eli Lilly Canada Inc. v. [read post]
25 Mar 2015, 4:42 am
It cited Mylan Laboratories, Inc. v. [read post]
